Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 435-441

  Flis, Sylwia ^a   Spławiński, Jacek ^a  

^a National Medicine Institute   (Poland)

Author keywords

5 Fluorouracil (5 FU); Colorectal cancer; Oxaliplatin; Sulindac sulfide; Synergism

Indexed keywords

FLUOROURACIL; OXALIPLATIN; SULINDAC SULFIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL SURVIVAL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BALB 3T3 CELLS; CELL CYCLE; CELL GROWTH PROCESSES; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FLUOROURACIL; HT29 CELLS; HUMANS; MICE; ORGANOPLATINUM COMPOUNDS; SULINDAC;

EID: 61449117031     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
2. Tebbutta NC, Cattellb E, Midgleyb R, Cunninghama D and Kerrb D: Systemic treatment of colorectal cancer. EJC 38: 1000-1015, 2002.
3. Cruz-Correa M, Hylind, Linda M, Romans KE, Booker SV and Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 122: 641-645, 2002.
4. Hilmi I and Goh KL: Chemoprevention of colorectal cancer with nonsteroidal anti inflammatory drugs. Chin J Dig Dis 7: 1-6, 2006.
5. Kismet K, Akay MT, Abbasoglu O and Ercan A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detection and Prevention 28: 127-142, 2004.
6. Janne PA and May er RJ: Chemoprevention of colorectal cancer N Engl J Med 342: 1960-1968, 2000.
7. de Groot DJA, de Vries EGE, Groen HJM and de Jong S: Non-steroidal anti inflammatory drugs to potentiates chemotherapy effects: From lab to clinic. Crit Rev Oncol/Hematol 61: 52-69, 2007.
8. El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF and Philip PA: Phase-II study of dose-attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 67: 283-289, 2008.
9. Elwich-Flis S, Sołtysiak Pawluczuk D and Splawinski J: Antiangiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane (CAM). Hybridoma 22: 55-60, 2003.
10. Flis S, Sołtysiak Pawluczuk D, Jedrych A, Jastrzebski Z, Remiszewska M and Spławiński J: Angiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res 26: 3033-3042, 2006.
11. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R and Ahnen DJ: Apoptosis, primary accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 265: 1582-1584, 1997.
12. Gessner PK: Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105: 161-179, 1995.
13. Chou TC and Talalay P: Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 4: 450-45, 1983.
14. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
15. Peters GJ, Van Der Wilt CL, Van Moorsel CJA, Kroep JR, Bergman AM and Ackland SP: Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Therapeutics 87: 227-253, 2000.
16. Flis S: Antiangiogenic and pro-apoptotic effects of sulindac and its metabolites. Ph.D. Dissertation. Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland, 2005.
17. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF and Jodrell DI: Enhanced oxaliplatin-induced apoptosis following antisense Bcl-x1 down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3: 169-178, 2004.
18. Gourdier I, Crabbe L, Andreau K, Pau B and Kroemer G: Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23: 7449-7457, 2004.
19. Sniff SJ, Qiao L, Tsai L and Rigas B: Sulindac Sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma. Cells J Clin Invest 96: 491-503, 1996.
20. Peters GJ, van Groeningen CJ and Giaccone G: Fluorouracil (5-FU) pharmacokinetics in 5-FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor. J Clin Oncol 19: 4267-4272, 2001.
21. Kern W, Braess J, Böttger B, Kaufmann CC, Hiddemann W and Schleyer E: Oxaliplatin pharmacokinetics during a four-hour infusion. Clin. Cancer Res 5: 761-765, 1999.
22. Webster RG, Brain KL, Wilson RH, Grem JL and Vincent A: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146: 1027-1039, 2005.